Abstract:Trypanosoma cruzi and HIV coinfection can evolve with depression of cellular immunity and increased parasitemia. We applied quantitative PCR (qPCR) as a marker for preemptive antiparasitic treatment to avoid fatal Chagas disease reactivation and analyzed the outcome of treated cases. This mixed cross-sectional and longitudinal study included 171 Chagas disease patients, 60 coinfected with HIV. Of these 60 patients, ten showed Chagas disease reactivation, confirmed by parasites identified in the blood, cerebrospinal fluid, or tissues, 12 exhibited high parasitemia without reactivation, and 38 had low parasitemia and no reactivation. We showed, for the first time, the success of the timely introduction of benznidazole in the non-reactivated group with high levels of parasitemia detected by qPCR and the absence of parasites in reactivated cases with at least 58 days of benznidazole. All HIV+ patients with or without reactivation had a 4.0–5.1 higher chance of having parasitemia than HIV seronegative cases. A positive correlation was found between parasites and viral loads. Remarkably, treated T . cruzi/ HIV-coinfected patients had 77.3% conversion from positive to negative parasitemia compared to 19.1% of untreated patients. Additionally, untreated patients showed ~13.6 times higher Odds Ratio of having positive parasitemia in the follow-up period compared with treated patients. Treated and untreated patients showed no differences regarding the evolution of Chagas disease. The main factors associated with all-cause mortality were higher parasitemia, lower CD4 counts/μL, higher viral load, and absence of antiretroviral therapy. We recommend qPCR prospective monitoring of T . cruzi parasitemia in HIV+ coinfected patients and point out the value of pre-emptive therapy for those with high parasitemia. In parallel, early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and increasing survival. We also suggest an early antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy. Chagas disease, present on all continents, in HIV-infected patients with cellular immunodeficiency may lead to the multiplication of T . cruzi . Reactivation of Chagas disease is life-threatening, occurring in immunosuppressed patients and diagnosed by parasite detection in blood or tissues. Here, we employed the quantitative Polymerase Chain Reaction (qPCR) to detect the increase of parasite copies in the blood and other biological fluids. Twelve HIV-coinfected patients with increased parasitemia without reactivation and ten patients with Chagas disease reactivation were selected for antiparasitic treatment and compared with 38 HIV-coinfected untreated patients with low parasitemia. Antiparasitic treatment changed positive parasitemia to negative in 77.3% of treated patients, with or without reactivation, whereas 19% of untreated cases changed from positive to negative parasitemia, after 92 and 76 months of follow-up, respectively. Two patients with reactivation died before ten days of treatment, suggesting that the diagnosis and treatment were quite late. We recommend parasitemia monitoring by qPCR and point out the value of antiparasitic treatment to coinfected T . cruzi /HIV patients with high levels of parasites in the blood, alongside early antiretroviral introduction. We also suggest early antiparasitic treatment for all coinfected patients and the analysis of the role of benznidazole in the reduction of parasitemia and control of Chagas disease evolution.

Impact of gastrointestinal inoculation and benznidazole treatment on infection by Trypanosoma cruzi (Y strain, DTU TcII) in Swiss mice

Effects of Free and Nanoencapsulated Benznidazole in Acute Trypanosoma cruzi Infection: Role of Cholinergic Pathway and Redox Status

Benzonidazole treatment has a beneficial effect on cells infected with the Colombian strain of Trypanosoma cruzi

Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models

Schistosoma mansoni co-infection modulates Chagas disease development but does not impair the effect of benznidazole-based chemotherapy

The Association of Ponderal Benznidazole with its Ultra-high Diluted Formula Reduces the Toxic Effects and Allows Increasing of Dose in Dose-dependent Protocol in Mice Infected with Trypanosoma cruzi

Benznidazole treatment decreases IL-6 levels in Trypanosoma cruzi-infected human adipocytes differentiated from adipose tissue-derived stem cells

Aspirin treatment exacerbates oral infections by Trypanosoma cruzi

Preclinical evaluation of combined therapy with amiodarone and low-dose benznidazole in a mouse model of chronic Trypanosoma cruzi infection

Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs

Oral Pyronaridine Tetraphosphate Reduces Tissue Presence of Parasites in a Mouse Model of Chagas Disease

Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi /HIV coinfection

Interaction between peripheral blood mononuclear cells and Trypanosoma cruzi-infected adipocytes: implications for treatment failure and induction of immunomodulatory mechanisms in adipose tissue

Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice

Oral infectivity through carnivorism in murine model of Trypanosoma cruzi infection

Molecular detection and parasite load of Trypanosoma cruzi in digestive tract tissue of Chagas disease patients affected by megacolon.

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

Oral Trypanosoma cruzi Acute Infection in Mice Targets Primary Lymphoid Organs and Triggers Extramedullary Hematopoiesis

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection